期刊文献+

口服避孕药联合二甲双胍治疗多囊卵巢综合征的对照研究

Comparative study of the combination of oral contraceptives caplendus and metformin in the treatment of polycystic ovary syndrome
原文传递
导出
摘要 目的探讨口服避孕药(达因-35)联合二甲双胍治疗多囊卵巢综合征(PCOS)的临床疗效。方法 2010年1月至2012年1月在阜阳市人民医院就诊的PCOS患者120例,随机分为A、B两组。A组62例,应用达因-35联合二甲双胍治疗;B组58例,单用达因-35治疗,疗程均为3个月。结果 A、B两组临床症状改善情况比较差异无统计学意义(P>0.05)。A组治疗后睾酮(T)、黄体生成素(LH)、LH/卵泡刺激素(FSH)明显下降(P<0.05);B组治疗后T、LH、LH/FSH明显下降(P<0.05),腰臀比和体质量指数明显增加(P<0.05)。结论口服避孕药联合二甲双胍是治疗PCOS的最佳选择。 Objective To investigate the therapeutic effects of the combination of oral contraceptives caplendus(diane-35) and metformin on patients with polycystic ovary syndrome.Methods One hundred and twenty PCOS patients in Fuyang people’s hospital were randomly divided into two groups: group A and B.Sixty-two patients in group A were treated with the combination of diane-35 and metformin,while 58 patients in group B were just treated with diane-35,the period of treatment was three months.Results After three months of treatment,there were no significant differences of the clinical features improvement(P&gt;0.05);T,LH and LH/FSH ratio decreased significantly in group A and B(P&lt;0.05),WHR and BMI level of group B showed significant improvement,there were significant differences(P&lt;0.05).Conclusion Combined using diane-35 and metformin in the treatment of PCOS is the best therapeutic method.
作者 肖红
出处 《临床医学》 CAS 2013年第4期27-28,共2页 Clinical Medicine
关键词 达因-35 二甲双胍 联合应用 多囊卵巢综合征 Diane-35 Metformin Combined use Polycystic ovary syndrome
  • 相关文献

参考文献4

二级参考文献33

  • 1Azziz R,Woods KS,Reyna R,et al.The prevalence and features of the polycystic ovary syndrome in an unselected population[J].J Clin Endocrinol Metab,2004,89:2745-2749.
  • 2Adams J,Polson DW,Franks S.Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsute[J].Br Med J,1986,293:355-359.
  • 3Polson DW,Adams J,Wadsworth J,et al.Polycystic ovaries a common finding in normal women[J].Lancet,1988,16:870-872.
  • 4Clayton RN,Ogden V,Hodgkinson J,et al.How common are polycystic ovaries in normal women and what is the insignificance for the infectility of the population?[J].Clin Endocrinol,1972,37:127-134.
  • 5Farguan CM,Bindsall M,Manning P,et al.The prevalence of polycystic ovaries on ultrasound scanning in a population of randomly selected women[J].Aust N Z J Obstet Gynecol,1994,34:67-72.
  • 6Michelmone KF,Balen AH,Dungen DB,et al.Polycystic ovaries and associated clinical and biochemical features in young women[J].Clin Endocrinol,1999,51:779-786.
  • 7Koivunen R,Lantikainen T,Tomas C,et al.The prevalence of polycystic ovaries in healthy women[J].Acta Obstet Gynecol Scanal,1999,78:137-141.
  • 8Fox R.Transvaginal ultrasound appearances of the ovary in normal women and hirsute women with oligomennorrhea[J].Aust N Z J Obstet Gynecol,1999,39:63-68.
  • 9Carmina E,Lobo RA.Do hyperandrogenic women with normal menses have polycystic ovary syndrome?[J].Fertil Steril,1997,71:319-322.
  • 10Solomon CG.The epidemiology of polycystic ovary syndrome:prevenlance and associated disease risk[J].Endocrinol Metab Clin North Am,1999,28:247-264.

共引文献197

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部